Technology Networks

Calando Pharmaceuticals

Calando Pharmaceuticals,
Inc.
2585 Nina Street
Pasadena,
CA 91107
USA




Tel: 626.305.9322
Fax: 626.305.9094
Email Us

Print Email to a friend

Calando Pharmaceuticals is a biopharmaceutical company focused on developing and commercializing proprietary technologies that will lead to the therapeutic use of RNA interference, or "RNAi".

Calando brings together multiple proven non-viral delivery technologies that overcome the primary hurdle to efficient RNAi delivery with world-class experience in the fields of medicine, RNAi therapeutics, drug delivery and materials design.

Further Information: http://www.calandopharma.com/


Related news from our archive

Calando Publishes new Results of siRNA Delivery Using its RONDEL™ Technology in Sepsis
Paper published online in Shock demonstrates efficacious use of RONDEL™-formulated siRNA in murine model of sepsis.

Calando Patent Issued for Active Ingredient of Lead siRNA Drug Candidate, CALAA-01
According to Calando, its CALAA-01 is the first and only anti-cancer siRNA drug candidate currently undergoing human clinical trials.

Calando Pharmaceuticals Announces Next siRNA Therapeutic Candidate for Oncology
Calando announces development of a second siRNA oncology therapeutic, CALAA-02, targeting HIF-2alpha.

Calando Pharmaceuticals Phase II Clinical Study Opens to Patient Enrollment
Company has initiated the United States trial evaluating the safety and efficacy of -101 in patients with platinum-sensitive ovarian cancer.